Research Article
The Utility of Perirenal Fat in Determining the Risk of Onset and Progression of Diabetic Kidney Disease
Table 1
Comparison of clinical characteristics between the CG group and DM group.
| | | CG (n = 100) | DM (n = 959) | t | |
| | Gender (M/F) | 47/53 | 609/350 | −0.143 | 0.457 | | Age (years) | 59 (51–68) | 60 (49–70) | −1.211 | 0.110 | | HbA1C (%) | 5.87 ± 1.34 | 9.49 ± 2.58 | −22.655 | <0.001 | | FPG (mmol/L) | 5.47 ± 1.92 | 8.89 ± 3.80 | −14.995 | <0.001 | | ALB (g/L) | 47.64 ± 3.05 | 40.61 ± 5.30 | 20.087 | <0.001 | | Urea (mmol/L) | 6.19 ± 1.68 | 6.18 ± 3.58 | 0.022 | 0.983 | | UA (μmol/L) | 336.70 ± 112.62 | 359.40 ± 108.84 | −1.978 | 0.048 | | Tch (mmol/L) | 4.98 ± 1.06 | 5.12 ± 12.24 | −0.117 | 0.907 | | TG (mmol/L) | 2.13 ± 2.29 | 2.17 ± 2.05 | −0.178 | 0.859 | | HDL (mmol/L) | 1.24 ± 0.38 | 1.03 ± 0.32 | 6.164 | <0.001 | | LDL (mmol/L) | 3.07 ± 0.98 | 2.93 ± 5.75 | 0.225 | 0.882 | | Rx | | None (diet alone) | — | 86 (9.0) | — | — | | OHA (n, %) | — | 236 (24.6) | — | — | | Insulin ± OHA (n, %) | — | 568 (59.2) | — | — | | Antihypertensive drugs (n, %) | — | 430 (44.8) | — | — | | ACE-I/ARBs (n, %) | — | 252 (26.3) | — | — | | Hypolipidemic therapy (n, %) | — | 324 (33.8) | — | — | | PFT (cm) | 0.85 (0.62–1.09) | 1.20 (0.92–1.38) | −12.442 | <0.001 | | BMI (kg/m2) | 20.43 ± 1.11 | 24.66 ± 3.98 | −8.465 | <0.001 | | PFT/BMI (mm/kg/m2) | 0.41 (0.32, 0.50) | 0.52 (0.40, 0.61) | −13.233 | <0.001 |
|
|
CG: health control group; DM: type 2 diabetes group; HbA1C: glycated hemoglobin ratio; FPG: fasting plasma glucose; ALB: serum albumin; urea: serum urea nitrogen; UA: blood uric acid; Tch: total serum cholesterol; TG: triglycerides; HDL: serum high-density lipoprotein; LDL: serum low-density lipoprotein; PFT: perirenal fat thickness; BMI = weight (kg)/height2 (m2); OHA: oral hypoglycemic agent; Rx, prescription.
|
